Clobazam therapeutic drug monitoring: A comprehensive review of the literature with proposals to improve future studies

Therapeutic Drug Monitoring

Volumn 35, Issue 1, 2013, Pages 30-47

  De Leon, Jose ^a,b   Spina, Edoardo ^c   Diaz, Francisco J ^d  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

anticonvulsant; clobazam; CYP2C19; CYP3A4; drug monitoring

Indexed keywords

CLOBAZAM; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; ISOENZYME; NORCLOBAZAM;

ANTICONVULSANT ACTIVITY; CLINICAL STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DYSARTHRIA; ENZYME ACTIVITY; GENE FREQUENCY; HUMAN; LENNOX GASTAUT SYNDROME; MOTOR DYSFUNCTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEX DIFFERENCE; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANIMALS; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; BENZODIAZEPINES; CYTOCHROME P-450 CYP3A; DRUG MONITORING; HUMANS; INTELLECTUAL DISABILITY; SPASMS, INFANTILE;

EID: 84872845726     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31827ada88     Document Type: Review

References (98)

1. Ng YT, Collins SD. Clobazam. Neurotherapeutics. 2007;4:138-144.
2. Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs. 2012;26:229-244.
3. Reynolds DS. The value of genetic and pharmacological approaches to understanding the complexities of GABA(A) receptor subtype functions: the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav. 2008;90:37-42.
4. Seif-Eddeine H, Ng YT. Clobazam for patients with Lennox-Gastaut syndrome and epilepsy. Expert Rev Neurother. 2012;12:385-393.
5. Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77: 1473-1481.
6. Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009;50:1158-1166.
7. Bentué-Ferrer D, Tribut O, Verdier MC, et al. Therapeutic drug monitoring of clobazam. Therapie. 2010;65:225-231.
8. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195-235.
9. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239-1276.
10. de Leon J. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 and CYP2C19 (guest editorial). J Clin Psychopharmacol. 2007;27: 241-245.
11. de Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res. 2009;59:81-89.
12. de Leon J, Spina E, Diaz FJ. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing and translation into a message understandable to practicing clinicians. J Clin Psychopharmacol. 2009;29:201-205.
13. de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics. 2005;46:262-273.
14. de Leon JA. Practitioner's Guide for Prescribing Anticonvulsants and Mood Stabilizers for Adults With Intellectual Disabilities. 1st ed. New York, NY: Springer Verlag; 2012.
15. Sjöhvidberg EF, Larsen NE, Naestoft J. Dose-dependent kinetics of ethotoin in man. Clin Exp Pharmacol Physiol. 1975;2:185-192.
16. Brunton LL, Chabner B, Knollman B. Goodman & Hillman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011.
17. Tozer TN, Rowland M. Introduction to Pharmacokinetics and Pharmacodynamics. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006.
18. Diaz FJ, Santoro V, Spina E, et al. Drug dosage individualization in the presence of clinical or demographic factors that have random effects in a linear model. J Biopharm Stat. 2012;22:463-484.
19. Diaz FJ, Yeh HG, de Leon J. The role of statistical random-effects linear models in personalized medicine. Curr Pharmacogenomics Person Med. 2012;10:22-32.
20. Walzer M, Bekersky I, Blum RA, et al. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32:340-353.
21. Bun H, Monjanel-Mouterde S, Noel F, et al. Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam. Pharmacol Toxicol. 1990;67:136-140.
22. Greenblatt DJ, Divoll M, Puri SK, et al. Clobazam kinetics in the elderly. Br J Clin Pharmacol. 1981;12:631-636.
23. Monjanel-Mouterde S, Antoni M, Bun H, et al. Pharmacokinetics of a single oral dose of clobazam in patients with liver disease. Pharmacol Toxicol. 1994;74:345-350.
24. Ochs HR, Greenblatt DJ, Lüttkenhorst M, et al. Single and multiple dose kinetics of clobazam, and clinical effects during multiple dosage. Eur J Clin Pharmacol. 1984;26:499-503.
25. Pullar T, Edwards D, Haigh JR, et al. The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazam. Br J Clin Pharmacol. 1987;23:317-321.
26. Pullar T, Haigh JR, Peaker S, et al. Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy. Br J Clin Pharmacol. 1987;24:793-797.
27. Rupp W, Badian M, Christ O, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol. 1979;7(suppl 1): 51S-57S.
28. Rupp W, Heptner W, Uihlen M, et al. Kinetic interaction of nomifensine with a 1,5-benzodiazepine (clobazam). Br J Clin Pharmacol. 1977;4(suppl 2):143S-146S.
29. Tedeschi G, Riva R, Baruzzi A. Clobazam plasma concentrations: pharmacokinetic study in healthy volunteers and data in epileptic patients. Br J Clin Pharmacol. 1981;11:619-622.
30. Vallner JJ, Kotzan JA, Stewart JT, et al. Plasma levels of clobazam after 10-, 20-, and 40-mg tablet doses in healthy subjects. J Clin Pharmacol. 1980;20:444-451.
31. Greenblatt DJ, Divoll M, Puri SK, et al. Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-dose accumulation. Clin Pharmacokinet. 1983;8:83-94.
32. Aylett SE, Cross JH, Berry D. Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. Dev Med Child Neurol. 2005; 48:612-615.
33. Montenegro MA, Arif H, Nahm EA, et al. Efficacy of clobazam as addon therapy for refractory epilepsy: experience at a US epilepsy center. Clin Neuropharmacol. 2008;31:333-338.
34. Naccarato M, Yoong D, Kovacs C, et al. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther. 2012;17:589-592.
35. Parmeggiani A, Posar A, Sangiorgi S, et al. Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19. Brain Dev. 2004;26:63-66.
36. Pok PR, Mauras M, De Saint Léger MN, et al. Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate. Leg Med (Tokyo). 2010;12:300-304.
37. Proença P, Teixeira H, Pinheiro J, et al. Forensic intoxication with clobazam: HPLC/DAD/MSD analysis. Forensic Sci Int. 2004;143: 205-209.
38. Contin M, Sangiorgi S, Riva R, et al. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit. 2002;24:737-741.
39. Bardy AH, Seppala T, Salokorpi T, et al. Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. Brain Dev. 1991;13:174-179.
40. Bun H, Coassolo P, Gouezo F, et al. Time-dependence of clobazam and N-demethylclobazam kinetics in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1986;24:287-293.
41. Contin M, Riva R, Albani F, et al. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit. 1999; 21:604-608.
42. Giraud C, Tran A, Rey E, et al. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004;32:1279-1286.
43. Kosaki K, Tamura K, Sato R, et al. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 2004;26:530-534.
44. Levy RH, Lane EA, Guyot M, et al. Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine- clobazam interaction in normal man. Drug Metab Dispos. 1983; 11:286-292.
45. Sennoune S, Mesdjian E, Bonneton J, et al. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit. 1992;14:269-274.
46. Seo T, Nagata R, Ishitsu T, et al. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. Pharmacogenomics. 2008;9:527-537.
47. Jawad S, Richens A, Oxley J. Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients. Br J Clin Pharmacol. 1984;18:873-877.
48. ONFI (clobazam). Highlights of Prescribing Information. Deerfield, IL: Lundbeck, Inc; 2011.
49. Roberts GW, Zoanetti GD. Clobazam and N-desmethylclobazam serum concentrations in endstage renal failure and hemodialysis. Ann Pharmacother. 1994;28:966-967.
50. Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet. 2006;45:13-31.
51. Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics. 2009;10: 1323-1339.
52. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol. 2006;2:171-182.
53. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30:1206-1227.
54. Anderson GD. Developmental pharmacokinetics. Semin Pediatr Neurol. 2010;17:208-213.
55. Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12:601-610.
56. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008;83:1-10.
57. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther. 2002;72:474-489.
58. Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol. 2007;3: 557-571.
59. Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology. 2000;61:174-185.
60. de Leon J, Susce MT, Johnson M, et al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr. 2009;14:19-34.
61. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47:75-85.
62. de Leon J, Arranz MJ, Ruaño G. Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med. 2008;28: 599-617.
63. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103-113.
64. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007; 100:4-22.
65. de Leon J, Santoro V, D'Arrigo C, et al. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012;8:2-24.
66. American Pharmacist Association. Drug Information Handbook. 21st ed. Hudson, OH: Lexi-Comp Inc; 2012.
67. Haigh JR, Pullar T, Gent JP, et al. N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy? Br J Clin Pharmacol. 1987;23:213-218.
68. Zifkin B, Sherwin A, Andermann F. Phenytoin toxicity due to interaction with clobazam. Neurology. 1991;41:313-314.
69. Haigh JR, Gent JP, Calvert R. Plasma concentrations of clobazam and its N-desmethyl metabolite; protection against pentetrazol-induced convulsions in mice. J Pharm Pharmacol. 1984;36:636-638.
70. Nakamura F, Suzuki S, Nishimura S, et al. Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia. 1996;37:728-735.
71. Fisher JL. Interactions between modulators of the GABA(A) receptor: stiripentol and benzodiazepines. Eur J Pharmacol. 2011;654: 160-165.
72. Voicu VA, de Leon J, Medvedovici AV, et al. New insights on the consequences of biotransformation processes on the distribution and pharmacodynamic profiles of some neuropsychotropic drugs. Eur Neuropsychopharmacol. 2012;22:319-329.
73. Arendt RM, Greenblatt DJ, Liebisch DC, et al. Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity. Psychopharmacology (Berl). 1987;93:72-76.
74. de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51:80-88.
75. Laux G, Koeppen D. Serum and cerebrospinal fluid concentration of clobazam and N-desmethylclobazam. Int J Clin Pharmacol Ther Toxicol. 1984;22:355-359.
76. Volz M, Christ O, Kellner HM, et al. Kinetics and metabolism of clobazam in animals and man. Br J Clin Pharmacol. 1979;7(suppl 1): 41S-50S.
77. Ballabio M, Caccia S, Garattini S, et al. Antileptazol activity and kinetics of clobazam and N-desmethyl-clobazam in the guinea-pig. Arch Int Pharmacodyn Ther. 1981;253:192-199.
78. Hendset M, Haslemo T, Rudberg I, et al. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry. 2006;39:121-127.
79. Bauer LA. Clinical Pharmacokinetics Handbook. New York, NY: McGraw-Hill; 2006.
80. Glauser TA, Pippenger CE. Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia. 2000;41 (suppl 8):S6-S15.
81. Alford C, Bhatti JZ, Curran S, et al. Pharmacodynamic effects of buspirone and clobazam. Br J Clin Pharmacol. 1991;32:91-97.
82. Bourin M, Auget JL, Colombel MC, et al. Effects of single oral doses of bromazepam, buspirone and clobazam on performance tasks and memory. Neuropsychobiology. 1989;22:141-145.
83. Patat A, Klein MJ, Hucher M. Effects of single oral doses of clobazam, diazepam and lorazepam on performance tasks and memory. Eur J Clin Pharmacol. 1987;32:461-466.
84. van der Meyden CH, Bartel PR, Sommers DK, et al. Effects of clobazam and clonazepam on saccadic eye movements and other parameters of psychomotor performance. Eur J Clin Pharmacol. 1989;37:365-369.
85. Wildin JD, Pleuvry BJ, Mawer GE, et al. Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br J Clin Pharmacol. 1990; 29:169-177.
86. Hindmarch I, Gudgeon AC. The effects of clobazam and lorazepam on aspects of psychomotor performance and car handling ability. Br J Clin Pharmacol. 1980;10:145-150.
87. Kleindienst-Vanderbeke G. Information processing and benzodiazepines. Neuropsychobiology. 1984;12:238-243.
88. Koeppen D. Review of clinical studies on clobazam. Br J Clin Pharmacol. 1979;7(suppl 1);139S-150S.
89. Brogden RN, Heel RC, Speight TM, et al. Clobazam: a review of its pharmacological properties and therapeutic use in anxiety. Drugs. 1980; 20:161-178.
90. Theis JG, Koren G, Daneman R, et al. Interactions of clobazam with conventional antiepileptics in children. J Child Neurol. 1997;12:208-213.
91. Neels HM, Sierens AC, Naelaerts K, et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med. 2004;42:1228-1255.
92. Guberman A, Couture M, Blaschuk K, et al. Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. Can J Neurol Sci. 1990;17:311-316.
93. Cenraud B, Guyot M, Levy RH, et al. No effect of food intake on clobazam absorption. Br J Clin Pharmacol. 1983;16:728-730.
94. Divoll M, Greenblatt DJ, Ciraulo DA, et al. Clobazam kinetics: intrasubject variability and effect of food on adsorption. J Clin Pharmacol. 1982;22:69-73.
95. Leahy JT, Chu-Shore CJ, Fisher JL. Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome. Neuropsychiatr Dis Treat. 2011;7:673-681.
96. Remy C. Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia. 1994;35(suppl 5):S88-S91.
97. Montenegro MA, Guerreiro CA. Role of clobazam in the treatment of epilepsies. Expert Rev Neurother. 2003;3:829-834.
98. Giarratano M, Standley K, Benbadis SR. Clobazam for treatment of epilepsy. Expert Opin Pharmacother. 2012;13:227-233.